Relevant bibliographies by topics / Fever multi-dose analysis / Journal articles
To see the other types of publications on this topic, follow the link: Fever multi-dose analysis.

Journal articles on the topic 'Fever multi-dose analysis'

Author: Grafiati
Published: 4 June 2025
Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Fever multi-dose analysis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Shieb, Mohamad, Ghadah Al-Sharif, Fatima Mazahir, Jaidev Nath, Walid Abuhammour, and Nidheesh Cheeyancheri Chencheri. "Case report: Encephalitis with Guillain-Barré Syndrome secondary to extensively multi-drug resistant Salmonella infection." Journal of the Pediatric Infectious Diseases Society 13, Supplement_4 (2024): 11. http://dx.doi.org/10.1093/jpids/piae093.031.

Full text
Abstract:
Abstract Background This case report presents a highly unusual and challenging medical case involving a 16-month-old previously healthy boy who developed encephalitis followed by Guillain-Barré Syndrome (GBS) as complications of multi-drug resistant Salmonella infection, despite an initial misdiagnosis of gastroenteritis and outpatient treatment with Cefixime. Methods The patient initially experienced an increase in stool frequency, accompanied by low-grade fevers, which was initially attributed to gastroenteritis. Outpatient treatment with oral Cefixime was started, but the child’s symptoms w
APA, Harvard, Vancouver, ISO, and other styles
2

Scarpace, Philip J., Bradley S. Bender, and Stephen E. Borst. "Escherichia coli peritonitis activates thermogenesis in brown adipose tissue: relationship to fever." Canadian Journal of Physiology and Pharmacology 69, no. 6 (1991): 761–66. http://dx.doi.org/10.1139/y91-113.

Full text
Abstract:
Fever is a complex and important nonspecific, host defense mechanism against infection. The generation of the heat necessary to increase body temperature may involve thermogenesis in brown adipose tissue. To investigate whether the febrile response to Escherichia coli peritonitis involves thermogenesis in brown adipose tissue, we assessed whole rat oxygen consumption and brown adipose tissue mitochondrial guanosine 5′-diphosphate binding. Non-lethal doses of E. coli, 1 × 106 to 1 × 108 colony forming units, induced a fever for greater than 8 h. In contrast, a dose of 1 × 109 colony forming uni
APA, Harvard, Vancouver, ISO, and other styles
3

Jahaj, Edison, Parisis Gallos, Melina Tziomaka, et al. "Telehealth-Based Information Retrieval and Extraction for Analysis of Clinical Characteristics and Symptom Patterns in Mild COVID-19 Patients." Information 15, no. 5 (2024): 286. http://dx.doi.org/10.3390/info15050286.

Full text
Abstract:
Clinical characteristics of COVID-19 patients have been mostly described in hospitalised patients, yet most are managed in an outpatient setting. The COVID-19 pandemic transformed healthcare delivery models and accelerated the implementation and adoption of telemedicine solutions. We employed a modular remote monitoring system with multi-modal data collection, aggregation, and analytics features to monitor mild COVID-19 patients and report their characteristics and symptoms. At enrolment, the patients were equipped with wearables, which were associated with their accounts, provided the respect
APA, Harvard, Vancouver, ISO, and other styles
4

Mays, T. A., J. Sarantopoulos, A. Tolcher, et al. "MDX-070, a human anti-plasma antibody, administered as either a single dose or as multiple doses to patients with hormone-refractory prostate cancer." Journal of Clinical Oncology 24, no. 18_suppl (2006): 14549. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.14549.

Full text
Abstract:
14549 Background: Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is specifically expressed in prostatic epithelial cells and up-regulated in hormone refractory prostate cancer (HRPC). MDX-070 is a HuMAb that recognizes conformational epitopes on PSMA, mediates anti-body-dependent cellular cytotoxicity (ADCC), and is internalized. The primary objective of these studies was to establish the safety and tolerability and maximum tolerated dose (MTD) of MDX070 in patients (pts) with HRPC. Secondary objectives included characterization of the pharmacokinetic (P
APA, Harvard, Vancouver, ISO, and other styles
5

Qiu, Huiying, Wu Depei, Aining Sun, et al. "Multi-Course of Moderate Dose Cytosine Arabinoside and Fludarabin in the Consolidation Therapy of Patients with De Novo Acute Myeloid Leukemia." Blood 118, no. 21 (2011): 4251. http://dx.doi.org/10.1182/blood.v118.21.4251.4251.

Full text
Abstract:
Abstract Abstract 4251 To investigate the long-term outcome of multi-course of moderate dose cytosine arabinoside and fludarabin in the consolidation therapy of patients with de novo acute myeloid leukemia (AML). Sixty-seven consecutive de novo AML patients, 38 males, 29 females, including M1 (5 cases), M2a (34 cases), M4 (11 cases), M5 (13 cases), M6 (2 cases), unclassified AML (1 cases), HAL (1 case), were enrolled in this retrospective analysis between 2006 to 2011. Their median age was 32.28 years (range 13–64 years). Cytogenetic analysis showed that 27 patients with normal karyotype, 11 p
APA, Harvard, Vancouver, ISO, and other styles
6

Hou, Liqiong, and Juan Li. "On-Demand Plerixafor Added to High-Dose Cyclophosphamide and Pegylated Recombinant Human Granulocyte Colony-Stimulating Factorin the Mobilization of Patients with Multiple Myeloma: High Effectiveness and Affordable Cost." Blood 142, Supplement 1 (2023): 6669. http://dx.doi.org/10.1182/blood-2023-173781.

Full text
Abstract:
Background Autologous stem cell transplantation(ASCT) still represents an integral part of treatment for patients with eligible newly diagnosed multiple myeloma. It is important to collect enough stem cells for two transplants in the first mobilization.The combination of high-dose cyclophosphamide(Cy) (3g/m 2) plus granulocyte colony-stimulating factor(G-CSF)and on-demand plerixafor has been considered the effective method as mobilization regimen, but G-CSF requires daily, multi-injection administration. Here, we performed a real-world analysis to evaluate the efficacy and cost of high-dose Cy
APA, Harvard, Vancouver, ISO, and other styles
7

Yang, I.-Ning, Chin-Li Lu, Hung-Jen Tang, et al. "Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis." PLOS ONE 17, no. 9 (2022): e0273676. http://dx.doi.org/10.1371/journal.pone.0273676.

Full text
Abstract:
Background COVID-19 vaccination is essential. However, no study has reported adverse events (AEs) after ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease (ESRD) on hemodialysis (HD). This study investigated the AEs within 30-days after the first dose of ChAdOx1 nCoV19 (Oxford-AstraZeneca) in ESRD patients on HD. Methods and findings A total of 270 ESRD patients on HD were enrolled in this study. To determine the significance of vascular access thrombosis (VAT) post vaccination, we performed a self-controlled case study (SCCS) analysis. Of these patients, 38.5% had local AEs;
APA, Harvard, Vancouver, ISO, and other styles
8

Tan, Peter T., Kate Reed, Patricia A. Walker, et al. "Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study." Blood 118, no. 21 (2011): 1529. http://dx.doi.org/10.1182/blood.v118.21.1529.1529.

Full text
Abstract:
Abstract Abstract 1529 Background: The management options for patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy remain limited. The combination of hypomethylating agent and deacetylase inhibitor (DACi) has been shown to be synergistic, both in terms of leukaemia cell killing and gene reactivation in vitro. Aim: To investigate the safety, tolerability and preliminary efficacy of combining the oral pan-DACi panobinostat (LBH589) with azacitidine in previously untreated MDS or AML, not fit for standard induction
APA, Harvard, Vancouver, ISO, and other styles
9

Vitanza, Nicholas A., Juliane Gust, Rebecca Ronsley, et al. "Abstract LB121: BrainChild-03: Intraventricular B7-H3 CAR T cells for recurrent/refractory central nervous system tumors and non-pontine diffuse midline glioma in children and young adults." Cancer Research 83, no. 8_Supplement (2023): LB121. http://dx.doi.org/10.1158/1538-7445.am2023-lb121.

Full text
Abstract:
Abstract Background: B7-H3 expression on central nervous system (CNS) tumors offers a potential therapeutic target for adoptive cellular therapy. Methods: A 3+3 statistical design was employed to assess the safety of repeated B7-H3 chimeric antigen receptor (CAR) T cells administered into the intracranial ventricular system (ICV) using an intrapatient dose escalation without lymphodepleting chemotherapy in pts 1-26 years of age with recurrent/refractory CNS tumors including (non-pontine) diffuse midline glioma (DMG) (NCT04185038, Arm B). Primary endpoints were feasibility to manufacture suffic
APA, Harvard, Vancouver, ISO, and other styles
10

Ali, Natasha, Raheel Iftikhar, Zeeshan Ahmed Khan, Usman Ahmed, Humera Mahmood, and Zeba Aziz. "DLBCL in Older Adults: Is Age Just a Number in LMIC?" Blood 144, Supplement 1 (2024): 6433. https://doi.org/10.1182/blood-2024-210455.

Full text
Abstract:
Background and objective: Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma in adults. Limited data is available from low middle income countries (LMIC) in patients aged more than 60 years, with DLBCL. Our objective was to determine the presentation, comorbidities, socioeconomic status (SES), treatment received and outcomes of elderly patients with DLBCL. Subjects and methods: We conducted a multi-centre, retrospective study from 2015 till 2023 and included all adult patients diagnosed with DLBCL. Patients aged more than 60 years were included in the analy
APA, Harvard, Vancouver, ISO, and other styles
11

Reece, D. E., V. Sanchorawala, U. Hegenbart, et al. "Phase I/II study of bortezomib (B) in patients with systemic AL-amyloidosis (AL)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 8050. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.8050.

Full text
Abstract:
8050 Background: AL is characterized by deposition of monoclonal immunoglobulin light chains leading to multi-organ failure and death. B (Velcade®) is a specific inhibitor of the 26S proteasome with activity in several malignancies. This mechanism of action raises concern of enhancing the amyloidogenic protein deposition and worsening of AL. This phase I/II study is to determine the maximum tolerated dose (MTD) and toxicity profile of B in pts previously treated for AL. Secondary objectives include the rate and duration of hematologic and organ responses. Methods: A 3+3 dose escalation design
APA, Harvard, Vancouver, ISO, and other styles
12

Niu, Jiaxin, Minal A. Barve, Alexander I. Spira, et al. "Intravenous (IV) infusion of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, as monotherapy in advanced solid tumors: Preliminary results from an ongoing phase 1/2a study." Journal of Clinical Oncology 41, no. 16_suppl (2023): e14689-e14689. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e14689.

Full text
Abstract:
e14689 Background: Oncolytic virotherapy has emerged as a promising anticancer treatment. To date, almost all oncolytic viruses (OVs) are delivered via intratumoral (IT) injection, which limits its broad clinical application. Systemic delivery of OVs, a more practical option for patients (pts) without injectable lesions, allows both primary tumor and metastases treated simultaneously. However, due to concerns for immune clearance and the potential cytokine storms, very few studies thus far are conducted using OVs intravenously. T3011 is a genetically modified, next-generation oncolytic HSV-1 e
APA, Harvard, Vancouver, ISO, and other styles
13

Madarang, Ellen, Jillian Lykon, Wenhui Li, et al. "Octogenarians with AML Can Have Durable Remissions with Venetoclax and Hypomethylating Agent Therapy Despite Significant Dose Reductions." Blood 138, Supplement 1 (2021): 1259. http://dx.doi.org/10.1182/blood-2021-151738.

Full text
Abstract:
Abstract Introduction Venetoclax in combination with a hypomethylating agent (VEN-HMA) has become a standard of care for older or unfit patients with newly diagnosed AML. Although primarily administered in the outpatient setting, VEN-HMA is associated with significant cytopenias and infectious complications, requiring careful monitoring and dose adjustments. Patients treated with VEN-HMA on clinical trials had a median age of ~75 years. The optimal dose and schedule, safety, and efficacy of VEN-HMA in octo- and nonagenarians is not clearly defined. Methods We performed a retrospective analysis
APA, Harvard, Vancouver, ISO, and other styles
14

Masuoka, Kazuhiro, Shigesaburo Miyakoshi, Shinsuke Takagi, et al. "Hemophagocytic Syndrome (HPS) Post Reduced Intensity Cord Blood Transplantation (RI-CBT) in Adult Patients with Hematological Diseases." Blood 106, no. 11 (2005): 2743. http://dx.doi.org/10.1182/blood.v106.11.2743.2743.

Full text
Abstract:
Abstract <Introduction> HPS are rare but often-fatal conditions characterized by an inappropriate and sustained activation of the cellular immune system leading to accumulation of activated macrophages and a cytokine storm. HPS consists of primary and secondary Hemophagocytic Lymphohistiocytosis (HLH). Secondary HLH occurs at any age and the genetic contribution remains uncertain. Clinical features in patients with HLH are fever, cytopenias, liver dysfunction, hepato-splenomegaly, and the presence of hemophagocytosis in the bone marrow as well as other reticuloendothelical tissue
APA, Harvard, Vancouver, ISO, and other styles
15

Ancuța, Diana-Larisa, Mădălina Preda, and Andrei-Alexandru Muntean. ""COAGULATION FACTORS, INFLUENCED OR NOT, IN THE REPEATED DOSE TOXICITY TEST OF A CANDIDATE VACCINE AGAINST SARS-COV-2?"." Romanian Archives of Microbiology and Immunology 81, no. 1 (2022): 7–14. http://dx.doi.org/10.54044/rami.2022.01.02.

Full text
Abstract:
"SARS-CoV-2 infection increases the risk of multi-organ systemic complications and venous and arterial thromboembolism. The development of vaccines has proven to be an effective method to combat severe forms of infection. Adverse effects reported after COVID-19 vaccination consisted of local injection site reaction, fatigue, myalgia, or fever as well as sporadic cases of vaccine-induced thrombotic immune thrombocytopenia, especially viral vector vaccines. Objectives: The aim of the study was to evaluate the repeated dose toxicity of a candidate vaccine against SARS-CoV-2, a test in which sever
APA, Harvard, Vancouver, ISO, and other styles
16

Blank, N., C. Schuetz, M. Hufnagel, et al. "POS1573 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH TRAPS (TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1162.2–1163. http://dx.doi.org/10.1136/annrheumdis-2023-eular.6191.

Full text
Abstract:
BackgroundAutoinflammatory periodic fever syndromes are characterized by severe systemic and organ inflammation as well as high burden for the patients and their families. Successful treatment was achieved in clinical trials and in real life with the interleukin-1β inhibitor canakinumab (CAN) leading to rapid remission of symptoms and normalization of laboratory parameters in most patients.ObjectivesThe present study explores the long-term efficacy and safety of CAN under routine clinical practice conditions in pediatric (age ≥2 years) and adult patients with autoinflammatory periodic fever sy
APA, Harvard, Vancouver, ISO, and other styles
17

Ronsley, Rebecca, Kristy Seidel, Prabha Narayanaswamy, et al. "CTIM-02. PIONEERING QUAD-TARGETING CAR T CELL THERAPY IN PEDIATRIC CNS TUMORS – ANALYSIS FROM THE INITIAL PATIENTS TREATED ON THE FIRST-IN-HUMAN PHASE 1 TRIAL BRAINCHILD-04." Neuro-Oncology 26, Supplement_8 (2024): viii84. http://dx.doi.org/10.1093/neuonc/noae165.0336.

Full text
Abstract:
Abstract BACKGROUND BrainChild-04 is a first-in-human clinical trial of quad-chimeric antigen receptor (CAR) T cell therapy for children and young adults with central nervous system (CNS) tumors. This trial administers repeated locoregional CAR T cells targeting B7-H3, EGFR, HER2, and IL-13Ralpha2 (“quad-CAR T cells”), leveraging multi-antigen targeting to address the tumor heterogeneity of high-grade CNS tumors. METHODS The primary endpoints are feasibility and safety, and secondary endpoints are disease response and correlative studies of CAR T cell activity. The trial utilized a Bayesian Op
APA, Harvard, Vancouver, ISO, and other styles
18

Ronsley, Rebecca, Michelle Choe, Kristy Seidel, et al. "IMMU-01. PIONEERING QUAD-TARGETING CAR T CELL THERAPY IN PEDIATRIC CNS TUMORS – ANALYSIS FROM THE INITIAL PATIENTS TREATED ON THE FIRST-IN-HUMAN PHASE 1 TRIAL BRAINCHILD-04." Neuro-Oncology 26, Supplement_4 (2024): 0. http://dx.doi.org/10.1093/neuonc/noae064.372.

Full text
Abstract:
Abstract BACKGROUND BrainChild-04 is a first-in-human clinical trial of quad-chimeric antigen receptor (CAR) T cell therapy for children and young adults with central nervous system (CNS) tumors. This trial administers repeated locoregional CAR T cells targeting B7-H3, EGFR, HER2, and IL-13Ralpha2 (“quad-CAR T cells”), leveraging multi-antigen targeting to address the tumor heterogeneity of high-grade CNS tumors. METHODS The primary endpoints are feasibility and safety, and secondary endpoints are disease response and correlative studies of CAR T cell activity. The trial utilized a Bayesian Op
APA, Harvard, Vancouver, ISO, and other styles
19

Zaoutis, Theoklis, Sonika Bhatnagar, Stephen I. Black, et al. "639. Short Course Therapy for Urinary Tract Infections (SCOUT) in Children." Open Forum Infectious Diseases 7, Supplement_1 (2020): S380. http://dx.doi.org/10.1093/ofid/ofaa439.833.

Full text
Abstract:
Abstract Background The AAP recommends 7 to 14-days of antimicrobials for the treatment of urinary tract infections (UTIs), one of the most common bacterial infections of childhood. However, most physicians routinely prescribe at least 10 days of therapy. Prior observational studies suggest that courses shorter than 10 days might be effective. Methods The primary objective was to determine if halting antimicrobial therapy in children who improved clinically after 5 days of therapy (short course therapy) results in a similar failure rate as children who continue antimicrobials for an additional
APA, Harvard, Vancouver, ISO, and other styles
20

Cortes, Jorge, D. W. Kim, F. Guilhot, et al. "Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START-A’ Phase II Study." Blood 108, no. 11 (2006): 2160. http://dx.doi.org/10.1182/blood.v108.11.2160.2160.

Full text
Abstract:
Abstract Dasatinib (SPRYCEL®, formerly BMS-354825) is a novel, oral, multi-targeted kinase inhibitor that induces complete hematologic and cytogenetic remissions in pts in all phases of im-r or im-i CML. START-A is an open-label study of dasatinib in pts with im-r or im-i AP-CML. Preliminary results with early follow-up suggested significant activity. The present report updates the results of this study with a minimum of 9 months of follow-up. Dasatinib was given orally at 70 mg twice daily (BID). Dose escalation to 100 mg BID was allowed for inadequate initial response and reduction to 50 or
APA, Harvard, Vancouver, ISO, and other styles
21

Berinstein, Neil, Kim Roos, Kathryn Mangoff, et al. "Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)." Blood 142, Supplement 1 (2023): 3037. http://dx.doi.org/10.1182/blood-2023-186347.

Full text
Abstract:
Background: Waldenström's macroglobulinaemia (WM) is an uncommon lymphoproliferative disorder. Although many options are available, an optimal first-line therapy for WM has not been defined. We postulated that combining bendamustine and rituximab (BR) with a next generation BTK inhibitor would result in deeper responses as measured by complete response (CR) and very good partial response (VGPR) rates, and provide a longer duration of response. Objectives: The primary objective of this trial is to document the CR and VGPR rates Methods: The BRAWM clinical trial combines BR with acalabrutinib in
APA, Harvard, Vancouver, ISO, and other styles
22

Nabhan, Chadi, Theodore Karrison, Justin Kline, et al. "Prospective Phase I Multi-Center Trial Incorporating Lenalidomide (LEN) into Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R) in Patients with Double Hit (DHL) or Double Expressing (DEL) Lymphomas: Final Results." Blood 128, no. 22 (2016): 4191. http://dx.doi.org/10.1182/blood.v128.22.4191.4191.

Full text
Abstract:
Abstract Background: There are no prospective studies that define best therapy for DHL (presence of c-MYC and BCL-2 translocations) or DEL (co-expression of c-MYC ³40% and BCL-2 ³50% by IHC). Retrospective data for both entities show suboptimal outcomes with R-CHOP and perhaps improved outcomes with intensified regimens such as DA-EPOCH-R. We conducted a phase I prospective multicenter study adding escalating doses of LEN to DA-EPOCH-R in pts with DHL or DEL. Herein, we report the final results of the dose-finding portion of this ongoing clinical trial. Patients and Methods: Eligible pts had D
APA, Harvard, Vancouver, ISO, and other styles
23

Oommen, P., T. Kallinich, J. Rech, N. Blank, J. Weber-Arden, and J. B. Kuemmerle-Deschner. "POS1376 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH HIDS (HYPER-IgD SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1027.2–1028. http://dx.doi.org/10.1136/annrheumdis-2022-eular.5063.

Full text
Abstract:
BackgroundHyper-IgD syndrome/mevalonate kinase deficiency (HIDS/MKD) is a rare autoinflammatory condition caused by a defect in the gene coding for mevalonate kinase. This periodic fever syndrome is characterized by severe systemic and organ inflammation. Treatment with interleukin-1β inhibitor canakinumab (CAN), approved and applied for treatment of HIDS/MKD patients since 2017 [1], resulted in rapid remission of symptoms and normalization of laboratory parameters in most patients in clinical trials [2] as well as in real-life.ObjectivesTo explore the long-term efficacy and safety of CAN unde
APA, Harvard, Vancouver, ISO, and other styles
24

Ospina Serrano, Aylen Vanessa, Ricardo Elias Bruges Maya, Isabel Munevar, et al. "Characteristics of SARSCOV2 infection in vaccinated patients with cancer in one Latin American country: Real world evidence from ACHOCC19-VAC study." Journal of Clinical Oncology 41, no. 16_suppl (2023): e18806-e18806. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e18806.

Full text
Abstract:
e18806 Background: According to results of previous ACHOC-C19 study, mortality in patients with cancer and COVID 19 infection in Colombia is 26%. The impact of vaccination was not evaluated prior to the implementation of this strategy worldwide in patients with cancer. We aimed to characterize SARSCOV 2 infection in a local cohort of vaccinated oncologic patients. Methods: The ACHOCC-19 VAC registry is a national multi-center observational cohort study. Data were collected between April 2021 and March 2022. Inclusion criteria were: age more than 18 years, confirmed diagnosis of cancer (solid t
APA, Harvard, Vancouver, ISO, and other styles
25

Wild, Aaron Tyler, Dan Laheru, Hao Wang, et al. "A randomized phase III multi-institutional study of TNFerade biologic with 5-FU and radiotherapy for locally advanced pancreatic cancer: Final results." Journal of Clinical Oncology 30, no. 15_suppl (2012): 4055. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4055.

Full text
Abstract:
4055 Background: TNFerade biologic (TNF) is a novel means of selective delivery of TNF-α to tumor cells by gene transfer through intratumoral (IT) injection. TNF is a replication deficient adenovirus vector containing TNF-α cDNA ligated downstream from a radiation-inducible Egr-1 promoter, allowing spatiotemporal constraint of TNF-α production to the radiation field. Herein we report the final results of a multi-center, randomized, open-label, controlled phase III trial of TNF with chemoradiotherapy for locally advanced pancreatic ductal adenocarcinoma (PDA). Methods: Pts with locally advanced
APA, Harvard, Vancouver, ISO, and other styles
26

Link, Charles J., Stephen Kee, George C. Prendergast, et al. "Clinical responses to SYNC-T therapy: In situ personalized cancer vaccination with intratumoral immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC)." Journal of Clinical Oncology 43, no. 16_suppl (2025): 2504. https://doi.org/10.1200/jco.2025.43.16_suppl.2504.

Full text
Abstract:
2504 Background: Metastatic castration-resistant prostate cancer (mCRPC) has a poor response to immunotherapy limited by both a low ORR and high frequency of severe immune-related adverse events. SYNC-T is a novel in situ therapy that synchronizes the presence of tumor antigens, an immune therapy drug, and immune cells in the tumor and locoregional lymph nodes. SYNC-T Therapy combines device-induced partial cryolysis of a targeted tumor to create a personalized multi-antigen vaccine, followed immediately by intratumoral infusion of the multitarget novel drug candidate SV-102, leading to T-cell
APA, Harvard, Vancouver, ISO, and other styles
27

Tang, Yongmin, Xiaojun Xu, Chan Liao, et al. "Retrospective Study on 46 Chinese Children with Acute Promyelocytic Leukemia: A Single Center Experience in China." Blood 108, no. 11 (2006): 4567. http://dx.doi.org/10.1182/blood.v108.11.4567.4567.

Full text
Abstract:
Abstract Acute promyelocytic leukemia (APL) is a specific type of hematopoietic malignancy, accounting for ~ 10% of the de novo acute myeloid leukemia (AML). During the old days, severe complications as disseminated intravascular coagulation (DIC) and intracranial hemorrhage were the most common causes of treatment failure after conventional chemotherapy without all-trans retinoic acid (RA). Owing to the application of RA for the induction treatment, the overall survival (OS), the disease free survival (DFS) and the event free survival (EFS) rates have been dramatically improved in adult patie
APA, Harvard, Vancouver, ISO, and other styles
28

Yang, Maolin, and Longjiang Li. "Multicenter, open-end, randomized controlled study using P53 gene recombinant adenovirus injection (rAd-p53) combined with chemotherapy for orofacial carcinoma (OFC): Phase IV clinical trial—Progress report and conclusion." Journal of Clinical Oncology 31, no. 15_suppl (2013): 6080. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.6080.

Full text
Abstract:
6080 Background: The gene therapy product (Gendicine, rAd-p53) had pre-market studies done around 1998 indicated its efficacy in the treatment of squamous cell nasopharyngeal carcinoma in multi-modality treatment regimen. Gendicine has been used successfully in treating over 40 cancer types since then. With the advancement in optimization of combined treatment methods over the years, there was a need for a medium term efficacy study. This report summarizes our phase IV study. Methods: Patient selection, intervention and allocation were done according to GCP and supported by statistical analysi
APA, Harvard, Vancouver, ISO, and other styles
29

Gaidzik, Verena I., Verena Mayr-Benedikter, Daniela Weber, et al. "Higher Dose of CPX-351 Is Associated with Prolonged Hematologic Recovery: Results from an Interim Safety Analysis of the Randomized, Phase III AMLSG 30-18 Trial." Blood 136, Supplement 1 (2020): 46–47. http://dx.doi.org/10.1182/blood-2020-138738.

Full text
Abstract:
Background: CPX-351, a liposomal formulation of daunorubicin and cytarabine in the fixed molar ratio (1:5), is approved for the treatment of adult patients (pts) with newly diagnosed acute myeloid leukemia (AML) with myelodysplasia-related changes and therapy-related AML (t-AML). To explore the potential benefit of CPX-351 in a broader indication, we initiated a randomized phase III study of CPX-351 vs "3+7" in pts ≥18 years (yrs) of age with AML and intermediate or adverse genetics according to 2017 European LeukemiaNet (ELN) risk categorization (AMLSG 30-18, NCT03897127). In the younger pts
APA, Harvard, Vancouver, ISO, and other styles
30

Fathi, Amir T., Daniel J. DeAngelo, Kristen E. Stevenson, et al. "Intensified Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): A Phase II Study from the Dana Farber Cancer Institute (DFCI) ALL Consortium." Blood 124, no. 21 (2014): 3714. http://dx.doi.org/10.1182/blood.v124.21.3714.3714.

Full text
Abstract:
Abstract Unlike the significant advances seen with intensive chemotherapy for pediatric acute lymphoblastic leukemia (ALL) over the last two decades, long-term outcomes among patients over age 50 remain poor, with median survival less than one year. This contrast has been attributed to high-risk chromosomal features, decreased compliance with and tolerance of effective therapies, and exposure to less intensive multi-agent regimens among adults with ALL. In recent years, more intensive chemotherapeutic paradigms, derived from pediatric protocols, have been studied in adult ALL. The purpose of t
APA, Harvard, Vancouver, ISO, and other styles
31

Karabulut, Y. "AB0699 RETROSPECTIVE ANALYSIS OF 52 SARS-COV2 POSITIVE PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASE: A SINGLE CENTER EXPERIENCE." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1382.1–1382. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3672.

Full text
Abstract:
Background:It is a generally accepted opinion that autoimmune and inflammatory rheumatic diseases or drugs used in the treatment of these conditions increase the risk of infection. During the pandemic period, the follow-up and treatment of patients who were diagnosed with rheumatic disease and used corticosteroid, immunosuppressive, biological or synthetic DMARDs and disease management during sars-cov2 infection still remain a problem.Objectives:In this study, it was aimed to share the demographic data of 52 patients with inflammatory rheumatic disease diagnosed with SARS-COV2 who were followe
APA, Harvard, Vancouver, ISO, and other styles
32

Katragadda, Lakshmikanth, Hagop M. Kantarjian, Guillermo Garcia-Manero, et al. "Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms." Blood 120, no. 21 (2012): 3606. http://dx.doi.org/10.1182/blood.v120.21.3606.3606.

Full text
Abstract:
Abstract Abstract 3606 Introduction: Rigosertib (ON01910.Na) is a non-ATP competitive multi-kinase inhibitor which differentially arrests tumor cells in G2-M stages and inhibits polo-like kinase and PI-3 kinase pathways with decreases of Cyclin-D1 and Akt phosphorylation. Earlier clinical studies in advanced solid tumors as well as in myelodysplastic syndrome (MDS) and acute leukemia reported a favorable toxicity profile and showed early evidence of clinical activity. Therefore, we initiated a study in acute myeloid leukemia (AML) investigating alternative schedules to determine the optimal do
APA, Harvard, Vancouver, ISO, and other styles
33

Raza, Dr Faiz Ahmed. "Chikungunya virus: An emerging public health challenge for Pakistan." Journal of Fatima Jinnah Medical University 15, no. 3 (2022): 100–101. http://dx.doi.org/10.37018/ycuk8608.

Full text
Abstract:
Chikungunya is a viral illness caused by the Chikungunya virus (CHIKV), an enveloped single-stranded linear RNA alphavirus belonging to the family Togaviridae. The CHIKV is transmitted by the same Aedes mosquito (Ae. aegypti and Ae. albopictus) responsible for transmitting the dengue and Zika viruses to humans.1 These viruses can co-circulate in an area and concurrent infections are possible in the same person.1
 Chikungunya is a viral illness caused by the Chikungunya virus (CHIKV), an enveloped single-stranded linear RNA alphavirus belonging to the family Togaviridae. The CHIKV is trans
APA, Harvard, Vancouver, ISO, and other styles
34

Hagenbeek, Anton, Torben Plesner, Jan Walewski, Andrzej Hellmann, Brian K. Link, and Lene W. Dalby. "HuMax-CD20 Fully Human Monoclonal Antibody in Follicular Lymphoma. First Human Exposure: Early Results of an Ongoing Phase I/II Trial." Blood 104, no. 11 (2004): 1400. http://dx.doi.org/10.1182/blood.v104.11.1400.1400.

Full text
Abstract:
Abstract HuMax-CD20 is a fully human monoclonal IgG1 antibody targeting a unique extracellular epitope of the CD20 molecule on B-cells. HuMax-CD20 stops growth of engrafted B-cell tumors in SCID mouse tumor models more efficiently than Rituximab®, and i.v. infusion of HuMax-CD20 in cynomolgus monkeys has led to profound, long lasting, dose-dependent B-cell depletion. A total of 40 patients with CD20+ relapsed or refractory follicular non-Hodgkin’s lymphoma grade I-II will be enrolled in this open-label, dose-escalating, international, multi-center clinical trial. Cohorts of 10 patients will re
APA, Harvard, Vancouver, ISO, and other styles
35

Mathisen, Michael S., Hagop M. Kantarjian, Elias Jabbour, et al. "Clofarabine-Containing Chemotherapy Does Not Increase the Risk of Infectious Complications in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)." Blood 118, no. 21 (2011): 4256. http://dx.doi.org/10.1182/blood.v118.21.4256.4256.

Full text
Abstract:
Abstract Abstract 4256 Background: Clofarabine is a purine nucleoside analog currently approved for relapsed pediatric acute lymphoblastic leukemia (ALL). Its role is also being investigated in various other hematologic malignancies, including AML. While desirably myelosuppressive, clofarabine is also lymphotoxic, which may impair cellular mediated immunity and result in higher rates of severe and/or atypical infections. Recently, an analysis of patients receiving clofarabine as salvage therapy for AML revealed a potentially increased risk for “unconventional” infections (Knoebel RW, Leuk Res,
APA, Harvard, Vancouver, ISO, and other styles
36

Dale, David C., Audrey Anna Bolyard, Tracy M. Marrero, et al. "The Natural History of Cyclic Neutropenia: Long-Term Prospective Observations and Current Perspectives." Blood 120, no. 21 (2012): 2141. http://dx.doi.org/10.1182/blood.v120.21.2141.2141.

Full text
Abstract:
Abstract Abstract 2141 Cyclic neutropenia (CyN) is an autosomal dominant and sporadically occurring hematological disease first described in 1910. Cyclic neutropenia is usually diagnosed in children before age 2 years based of regularly occurring fever, mouth ulcers, and recurrent skin or respiratory infections. In affected families, recognition is generally earlier than for the sporadic cases. Serial neutrophil counts usually show periods of very severe neutropenia (ANC< 0.2 × 109/L) at three week intervals and an intervening peak ANC less than 2.0 × 109/L. A reciprocal monocytosis often o
APA, Harvard, Vancouver, ISO, and other styles
37

Purroy, Noelia, Juan Bergua, Laura Gallur, et al. "Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group." Blood 118, no. 21 (2011): 593. http://dx.doi.org/10.1182/blood.v118.21.593.593.

Full text
Abstract:
Abstract Abstract 593 Objectives . This prospective multi-institutional phase IV study was designed within the Spanish PETHEMA Group to assess the efficacy and safety of dose adjusted EPOCH plus Rituximab (DA-EPOCH-R) infusional therapy (as previously reported*) in untreated patients with poor prognosis large B-cell lymphomas. All cycles were supported with G-CSF. Additional analysis of the clinical outcome and the influence of biomarkers associated with tumor proliferation (Ki67) and cellular differentiation was performed. Patients and Methods. Eighty-one untreated patients diagnosed of DLBCL
APA, Harvard, Vancouver, ISO, and other styles
38

Röllig, Christoph, Carsten Müller-Tidow, Andreas Hüttmann, et al. "Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial." Blood 124, no. 21 (2014): 6. http://dx.doi.org/10.1182/blood.v124.21.6.6.

Full text
Abstract:
Abstract Background: Sorafenib is a multi-kinase inhibitor with activity against several oncogenic kinases that may play a role in the pathogenesis of acute myeloid leukemia (AML). In-vitro data and results from non-randomized clinical trials suggest that sorafenib might be an effective drug for the treatment of AML. We present the results of the randomized placebo-controlled SORAML trial testing sorafenib versus placebo as add-on to standard induction and consolidation treatment in AML patients ≤60 years. Patients and Methods: Between March 2009 and October 2011, 276 patients from 25 centers
APA, Harvard, Vancouver, ISO, and other styles
39

Pollard, Jessica A., Todd A. Alonzo, Patrick A. Brown, et al. "Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031." Blood 134, Supplement_1 (2019): 292. http://dx.doi.org/10.1182/blood-2019-129557.

Full text
Abstract:
INTRODUCTION Sorafenib, a multi-kinase tyrosine kinase inhibitor (TKI) targets FLT3 internal tandem duplication (FLT3/ITD) mutations and has efficacy in adult FLT3/ITD+ AML. High allelic ratio (HAR) FLT3/ITD mutations (allelic ratio of > 0.4, referred to as FLT3/ITD+) confer poor prognosis in de novo pediatric AML. COG AAML1031 Arm C studied the feasibility and efficacy of adding sorafenib to standard chemotherapy and as a single agent maintenance therapy in pediatric HAR FLT3/ITD+ patients. METHODS The AAML1031 primary randomization (Arm A vs. B) has been previously reported (Aplenc et
APA, Harvard, Vancouver, ISO, and other styles
40

Zakaria, N. A., L. Mohd Isa, L. Mohamednor, et al. "AB1305 RHEUMATOID ARTHRITIS FLARE FOLLOWING COVID-19 VACCINATION IN MALAYSIAN POPULATION AND ITS ASSOCIATED RISK FACTORS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1881.2–1881. http://dx.doi.org/10.1136/annrheumdis-2023-eular.799.

Full text
Abstract:
BackgroundFlare of Rheumatoid Arthritis (RA) following COVID-19 vaccination has been reported with a low occurrence observed in those patients with disease remission. However, no local data is available in our multi-ethnic Malaysian population.ObjectivesTo evaluate the prevalence of RA flare in Malaysian patients following COVID-19 vaccination and its associated risk factors.MethodsThis was a cross-sectional study assessing RA flare based on patient-reported disease flare through self-administered questionnaires and physician-reported flare. Patient self-reported disease flare was defined as ‘
APA, Harvard, Vancouver, ISO, and other styles
41

Oo, Yadana, Liana Srisawitri, and Min Zaw Thein. "The Chaos of the Hematology-Rheumatology Border: Adult Onset Still Disease-Associated Macrophage Activation Syndrome." Blood 144, Supplement 1 (2024): 5369. https://doi.org/10.1182/blood-2024-194658.

Full text
Abstract:
Introduction Macrophage Activation Syndrome (MAS) is an under-recognized hematologic disorder associated with rheumatological diseases, including Adult Onset Still's Disease (AOSD). AOSD is a rare inflammatory disorder primarily affecting adults and characterized by immune dysfunction which can exacerbates MAS. If MAS is not promptly treated, it can lead to critical illness and lethal. The following is a clinical case presenting severe AOSD-associated MAS. Case Report A 37-year-old Caucasian female with a past medical history of mesiotemporal lobe epilepsy and uterine fibroids was initially ad
APA, Harvard, Vancouver, ISO, and other styles
42

Sacchi, Stefano, Samantha Pozzi, Marina Cesaretti, et al. "Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma." Blood 122, no. 21 (2013): 4383. http://dx.doi.org/10.1182/blood.v122.21.4383.4383.

Full text
Abstract:
Abstract Background Advanced-stage, relapsed indolent non follicular lymphomas (INFLs) have a relatively poor prognosis, with low complete response to conventional chemotherapy and short survival. Thus, there is a need for innovative treatment with high efficacy and a good safety profile. Lenalidomide (R®) is an immunomodulatory drug with a direct tumoricidal effect and action on T, NK and stromal cells that may enhance antibody-dependent cell mediated cytotoxicity as well as the development of specific anti-tumor immune responses. These immunologic effects may synergize with the action of rit
APA, Harvard, Vancouver, ISO, and other styles
43

Röllig, Christoph, Carsten Müller-Tidow, Andreas Hüttmann, et al. "Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial." Blood 120, no. 21 (2012): 144. http://dx.doi.org/10.1182/blood.v120.21.144.144.

Full text
Abstract:
Abstract Abstract 144 Background: Sorafenib is a multi-kinase inhibitor with activity against several oncogenic kinases, which may play a role in the pathogenesis of acute myeloid leukemia (AML). In-vitro data and results from non-randomized clinical trials suggest that sorafenib might be an effective drug for the treatment of AML. So far, no randomized-controlled data are available for treatment of newly diagnosed AML patients up to the age of 60 years. We present the first results from the randomized placebo-controlled SORAML trial of the Study Alliance Leukemia (SAL). Patients and Methods:
APA, Harvard, Vancouver, ISO, and other styles
44

Chong, Geoffrey, Denise Lee, Sze Ting Lee, et al. "First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study." Journal of Clinical Oncology 42, no. 16_suppl (2024): 7070. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.7070.

Full text
Abstract:
7070 Background: Standard 1L immunochemotherapy in FL is highly effective but not without significant toxicity. Up to 75% of FL patients (pts) have grade 3-5 adverse events (AEs), primarily infection and myelosuppression. More tolerable approaches are needed. PD1/PDL1 inhibitors are active in FL. A+O yield responses in 57% of rituximab-refractory FL pts (Palomba 2017). Our phase 2 study of 1L nivolumab + rituximab in FL yielded 92% overall response rate (ORR), (54% Complete Response (CR)). Toxicity compared favourably with chemotherapy: 41% grade 3-5 AEs (Hawkes 2021). FL is sensitive to low d
APA, Harvard, Vancouver, ISO, and other styles
45

Stein, Eytan M., Guillermo Garcia-Manero, David A. Rizzieri, et al. "A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition." Blood 126, no. 23 (2015): 2547. http://dx.doi.org/10.1182/blood.v126.23.2547.2547.

Full text
Abstract:
Abstract Introduction: Aberrant fusion proteins involving the MLL histone methyltransferase (HMT) result in recruitment of another HMT, DOT1L, to a multi-protein complex. This leads to abnormal methylation of Histone H3 lysine 79 (H3K79) at MLL target genes and enhanced expression of leukemogenic genes such as HOXA9 and MEIS1 ( Krivstov, 2007). Pinometostat is a small molecule inhibitor of DOT1L with sub-nanomolar affinity and >37,000 fold selectivity against non-MLL HMTs. Pinometostat treatment of MLL-rearranged cells and xenografts reduced histone H3K79 methylation, decreased MLL target g
APA, Harvard, Vancouver, ISO, and other styles
46

Czerwinski, Debra K., Steven R. Long, Michael Khodadoust, et al. "Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN." Blood 126, no. 23 (2015): 1539. http://dx.doi.org/10.1182/blood.v126.23.1539.1539.

Full text
Abstract:
Abstract BACKGROUND: Non-Hodgkin B cell lymphomas are often infiltrated by immune effector cells including T, NK and dendritic cells. But despite their presence within the tumor they fail to control tumor growth. Some T cells can even play a supportive role to maintain the tumor and prevent the function of anti-tumor immune cells. Regulatory T cells (TRegs) function normally to dampen immune responses and prevent auto-immunity by direct cell contact or by secreting suppressive cytokines i.e. TGF-b and Interleukin-10. Follicular Lymphoma tumor cells can induce the conversion of CD4 T cells into
APA, Harvard, Vancouver, ISO, and other styles
47

Hughes, Mitchell E., Daniel J. Landsburg, Daniel J. Rubin, et al. "Clinical Outcomes of Venetoclax Therapy in Patients with Relapsed/Refractory (r/r) Non Hodgkin Lymphomas (NHL)." Blood 132, Supplement 1 (2018): 1706. http://dx.doi.org/10.1182/blood-2018-99-111194.

Full text
Abstract:
Abstract Introduction: Venetoclax (VEN) is a highly effective agent for chronic lymphocytic leukemia (CLL) that targets BCL-2. Thus, it has been hypothesized to have efficacy in NHL and tested in phase-1/2 studies (Gerecitano JF, Blood 2015; de Vos S, Blood 2015; Davids MS, J Clin Oncol 2017). Overall response rates (ORR) observed in r/r NHL were 44% for all subtypes combined, 38% for follicular lymphoma (FL), 75% for mantle cell lymphoma (MCL), and 18% for diffuse large B-cell lymphoma (DLBCL). The adverse effect profile was consistent with the labeling despite dose escalation to doses higher
APA, Harvard, Vancouver, ISO, and other styles
48

Ujjani, Chaitra S., Catherine Lai, Lori A. Leslie, et al. "Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma." Blood 136, Supplement 1 (2020): 46–47. http://dx.doi.org/10.1182/blood-2020-136219.

Full text
Abstract:
Background: Ibrutinib (I) and venetoclax (V) have each demonstrated modest single-agent activity in relapsed/refractory follicular lymphoma (FL) (Gopal A, JCO 2018; Davids M, JCO 2017). Preclinical data have shown synergy with these agents in B-cell cell lines (Kuo H, Mol Cancer Ther 2017). Based on these observations, we proposed the first trial to combine I and V in FL. Results from the phase Ib portion of this multi-institutional investigator-initiated trial are presented here (NCT02956382). Methods: This phase Ib/II trial is open at Georgetown/Lombardi CCC, Hackensack/John Theurer CC, and
APA, Harvard, Vancouver, ISO, and other styles
49

Andreeff, Michael, Kevin R. Kelly, Karen Yee, et al. "Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia." Blood 120, no. 21 (2012): 675. http://dx.doi.org/10.1182/blood.v120.21.675.675.

Full text
Abstract:
Abstract Abstract 675 Background: Activation of the p53 pathway by inhibition of its negative regulator MDM2 has been proposed as a novel strategy for cancer therapy. We report the final results of the Phase 1 leukemia trial of RG7112, a small molecule antagonist of MDM2 which activates p53 by disrupting the p53-MDM2 interaction. Methods: The trial was designed as a multi-center, open-label Phase 1 MAD study of patients with relapsed/refractory leukemia treated with escalating doses of single agent RG7112 in two strata: A:AML, ALL, CML-BC; and B:CLL and S-CLL. RG7112 was administered orally da
APA, Harvard, Vancouver, ISO, and other styles
50

Stokes, Michael, Danielle Bradshaw, Yazmin Reategui, et al. "Hidac Consolidation Cycles May Impede Stem Cell Transplant Planning for High-Risk Acute Myeloid Leukemia Patients." Blood 142, Supplement 1 (2023): 5854. http://dx.doi.org/10.1182/blood-2023-191220.

Full text
Abstract:
Background Acute myeloid leukemia (AML) is a clonal aggressive hematologic neoplasm characterized by arrested myeloid maturation, resulting in the accumulation of myeloid blasts in bone marrow, blood, and other tissues. Cytogenetic and molecular characteristics further stratify AML into favorable, intermediate, or high-risk classifications; with high-risk including DEK-NUP214, KMT2A-rearrangement, BCR-ABL1, GATA2, MECOM, deletion 5q, abnormal 17p, complex or monosomal karyotype, wild type NPM1 and FLT3-ITD, or mutated: RUNX1, ASXL1, or TP53. In fit and eligible patients, therapy for high-risk
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography